Table 2.
Prevalence of rifampicin-resistant M. tuberculosis in each variable among the total M. tuberculosis cases using Gene Xpert MTB/RIF assay, DMRH, 2015
| Variables | Resistance pattern | P value | |
|---|---|---|---|
| Resistance N (%) |
Sensitive N (%) |
||
| Age, years | |||
| ≤10 | 2 (22.2) | 7 (77.8) | 0.02 |
| 11–17 | 1(14.3) | 6 (83.6) | |
| 18–30 | 3 (6.7) | 43 (93.3) | |
| 31–40 | 0 | 25 (100) | |
| 41–50 | 5 (33.3) | 10 (66.7) | |
| 51–60 | 0 | 9 (100) | |
| 61–92 | 1 (16.7) | 5 (83.3) | |
| Sex | |||
| Male | 8 (11.3) | 64 (88.7) | 0.77 |
| Female | 4 (8.9) | 41 (91.1) | |
| Residence | |||
| Urban | 5 (17.9) | 53 (91.2) | 0.76 |
| Rural | 7 (11.9) | 52 (88.1) | |
| HIV infection | |||
| Positive | 5 (17.9) | 24 (82.1) | 0.17 |
| Negative | 7 (8) | 81 (92) | |
| Reason for diagnosis | |||
| Presumptive TB | 3 (5.9) | 49 (94.1) | 0.22 |
| Presumptive DR TB | 9 (13.8) | 56 (86.2) | |
| Treatment history with anti-TB drugs | |||
| Previously treated | 7 (17.1) | 34 (82.9) | 0.11 |
| Previously untreated | 5 (6.7) | 71 (93.3) | |
| Presumptive DR TB | |||
| New | 3 (10.7) | 25 (89.3) | 0.87 |
| Relapse | 5 (19.2) | 21 (80.8) | |
| Failure | 2 (14.3) | 12 (91.7) | |
| MDR-contact | 0 | 1 | |
| Site of presumptive TB | |||
| Pulmonary | 6 (9.4) | 58 (90.6) | 0.77 |
| Extra pulmonary | 6 (11.3) | 47 (88.7) | |
| Specimen type | |||
| Respiratory (sputum) | 6 (9.5) | 58 (90.6) | 0.67 |
| Non-respiratory | 6 (11.3) | 47 (88.7) | |
| Type of non-respiratory specimen | |||
| Pus | 4 (8.5) | 43 (91.5) | |
| Peritoneal fluid | 0 | 2 | |
| Lymph node aspirate | 0 | 1 | |
| Pleural fluid | 2 | 1 | |
| Total | 12 (10.3) | 105 (89.7) | |
RIF rifampicin resistant, MTB M. tuberculosis, DR TB drug resistant tuberculosis